Well stated!! This stock is being accumulated for a reason. I find the spiked volume on the German exchange interesting.
I agree that the pipeline will be sold as a package. That can play out in a few different ways. Reverse merger with a company synergistic to Biodel; one with deep pockets etc... Another possibility, is a sale for cash and or stock of the pipeline and then a reverse merger with another compelling company. There are lots of possibilities. The good news is that the principals have a major vested interest in creating maximum shareholder value.
Not true. The money and no debt and low market cap is highly meaningful to another company seeking a reverse merger. The pipeline's value at this point is for the most part is not very high. This not my view but the streets. The price and the market cap essentially represents that.
Disagree. Even if the pipeline is not valuable, which is debatable, the stock is still very attractive; 35 million in the bank, low market cap, no dilutive overhang, that I can find. The real variable is what company is reverse merging into Biodel. If they play this right and the other company has substance, the stock could fly depending on the terms. The reverse merger is not without consequences. The other companies principals will be issued stock. The bankers will be paid fees. When the dust settles Wall Street will determine value. I disagree with prior statements that you made about offers to buy Biodel. Any offer would have been publicly disclosed. The possibility of a reverse merger with a reverse split is also possible. NRX is in the same relative position as Biod. The company has cash, no debt and a very low market cap. Their pipeline was also very attractive for treatment of kidney disease and they too announced the same plan as Biodel. Yet both stock are languishing. Hard to say why. In the case of NRX, a once high flying biotech stock, net institutional buying is up. In the case of Biodel, 23 million shares were sold but to whom is anyone's guess. I doubt very much the market.
That is not at all accurate. The institutions sold most of their shares over the prior 3 months.Actually, 23 million shares in total. Institutional ownership plunged from 79% to only 19% This information is found on NASDAQ website. During that period a couple of institutions did buy some shares but again the total institutional position is around 19%.
I find it very interesting that Amgen enters into a substantive agreement with Unilife for licensing their delivery systems and at the same time BIOD is restructuring and seeking a strategic alliance etc.. Would it be such a stretch that it is Amgen who is the suitor?
Is that why two MAJOR funds just bought in? Addage being on who doubled their position to 3 million shares